WallStSmart

ResMed Inc (RMD)vsSpotify Technology SA (SPOT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Spotify Technology SA generates 217% more annual revenue ($17.53B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 15.4%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 73/100 (B).

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

SPOT

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 8.5Value: 4.0Quality: 7.5
Piotroski: 4/9Altman Z: 2.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued
SPOTSignificantly Overvalued (-44.3%)

Margin of Safety

-44.3%

Fair Value

$337.63

Current Price

$417.83

$80.20 premium

UndervaluedFair: $337.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

SPOT4 strengths · Avg: 9.5/10
Return on EquityProfitability
38.0%10/10

Every $100 of equity generates 38 in profit

EPS GrowthGrowth
222.4%10/10

Earnings expanding 222.4% YoY

Market CapQuality
$87.44B9/10

Large-cap with strong market position

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

SPOT3 concerns · Avg: 4.0/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

P/E RatioValuation
28.2x4/10

Moderate valuation

Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bull Case : SPOT

The strongest argument for SPOT centers on Return on Equity, EPS Growth, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 15.8%.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : SPOT

The primary concerns for SPOT are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

SPOT carries more volatility with a beta of 1.55 — expect wider price swings.

RMD is growing revenue faster at 10.8% — sustainability is the question.

SPOT generates stronger free cash flow (845M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (73/100 vs 64/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Spotify Technology SA

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Spotify Technology SA, provides audio streaming services worldwide. The company is headquartered in Luxembourg, Luxembourg.

Want to dig deeper into these stocks?